These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19469628)

  • 1. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients.
    Naiki T; Okamura T; Kawai N; Sakagami H; Yamada Y; Fujita K; Akita H; Hashimoto Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2009; 10(1):71-4. PubMed ID: 19469628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
    Garcia JA; Weinberg V; Small EJ
    Clin Prostate Cancer; 2005 Sep; 4(2):113-7. PubMed ID: 16197612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.
    Kitamura T
    Int J Urol; 2001 Feb; 8(2):33-6. PubMed ID: 11240822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
    Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
    Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
    Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
    Lubiniecki GM; Berlin JA; Weinstein RB; Vaughn DJ
    Cancer; 2004 Dec; 101(12):2755-9. PubMed ID: 15536625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
    Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.